Source comparison
Thymosin Alpha-1 vs. Other Immune-Modulating Peptides: Research Protocol Comparison
Thymosin Alpha-1 TLR agonist; enhances dendritic cell maturation and NK cell activity 1.6–3.2mg twice weekly subcutaneously Moderate. Pilot studies show 30–40% fatigue reduction at 12 weeks in CFS/ME patients Refrigerate 2–8°C; 28-day stability post-reconstitu
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR agonist; enhances dendritic cell maturation and NK cell activity
- 1.6–3.2mg twice weekly subcutaneously
- Moderate. Pilot studies show 30–40% fatigue reduction at 12 weeks in CFS/ME patients
- Refrigerate 2–8°C; 28-day stability post-reconstitution
- Best-studied immune modulator for chronic immune activation syndromes; reproducible results across independent trials
- Thymalin
- Thymic extract; broad immune stimulation via multiple thymic peptides
- 5–10mg daily for 10-day cycles
- Limited. Primarily studied in age-related immune decline, not CFS/ME specifically
- Refrigerate 2–8°C; shorter post-reconstitution window (7–10 days)
- Broader but less targeted than Tα1; useful for general immunosenescence but lacks CFS/ME-specific trial data
- BPC-157
- Promotes angiogenesis and tissue repair; indirect immune modulation
- 250–500mcg once daily
- Minimal. Primarily studied for gut/tissue healing, not immune dysregulation
- Refrigerate 2–8°C; 28-day stability
- Not an immune modulator; occasionally used alongside Tα1 in protocols targeting gut-immune axis dysfunction
- LL-37 (Cathelicidin)
- Antimicrobial peptide; direct pathogen clearance and immune signaling
- 2–5mg twice weekly
- Emerging. Small case series suggest benefit in chronic Lyme and viral reactivation fatigue
- Refrigerate 2–8°C; light-sensitive (store in amber vials)
- Promising for pathogen-driven fatigue but lacks large-scale CFS/ME trials; mechanism overlaps with Tα1 in NK cell activation